Her name is Theresa May and she is the leading candidate to challenge Boris Johnson for Prime Minister. She is also a recently diagnosed Type 1 diabetic. Let's get her on Afrezza, and maybe we can start selling the drug in the UK.
When they did the secondary in May, each share came with a warrant with a strike price of $1.50. There were 50 million shares and an equal number of warrants. I think so anyway.
Then why did he hire an independent sales force? If we're combining efforts with DXCM, we should have been able to rely on their sales force, no?
We issued 50 million $1.50 warrants recently. Am I correct that we get $75 million if the stock goes above $1.50?
No it doesn't mean more frequent dosing. It's a mealtime insulin, not a basal insulin. And so what it leaves the body faster? It causes fewer hypoglycemic events, which hospitalizes 100,000 people a year and can be fatal. Now I'm putting you back on ignore where you belong.
The news was bullish, but the market is manic-depressive when it comes to MNKD. Right now it's in its depressive, "show me the money" phase. When the sales start flowing in a few weeks, the stock will jump.
SLIM. Mannkind represents .7% of total assets as of inception, or about $17 million. If they bought shares at $1, they own over 3% of the company. If it catches on, that'll be another source of buying.
If we hit 2000 NRX per week, MNKD will go nuts.
We only need to last long enough to show Afrezza is viable. That's 3-6 months. If the SP goes above $1.50, another $75 million from the warrants will be enough to last us into 2017. But if sales go up, we'll be sold before then.
Going alone is a bluff for leverage in negotiating a better deal and at least show this is a viable drug. If sales can increase materially by Q4, this company will be sold.
I almost hope you are a fake doctor because I'd hate to think about such a mentally deranged person giving medical care.
Add me to the chorus. If anything positive is announced or going to be at ADA, expect a buyout beforehand or shortly after. Won't be for much, though.
Going from bad to worse.
I've never seen a company so inept at the basic "blocking and tackling" of corporate governance. How could he not have had the paperwork done in time for a conference call, only to be ready an hour later? That's gross incompetence, and good intentions and trying hard don't make it better. Thank God Matt hired Castagna, a real professional, to market this drug. Because Matt is an incompetent CEO.
If it hits $1.50, which is just .20 higher than where it closed, the effective dilution price is $1.28, give or take. That's just 2 cents off the close. I hate being lied to and never trusted Matt and now I trust him even less if that's possible, but at least we can make it to see if Afrezza is a marketable drug or not.
I disagree with almost everything mgmt does, but if the warrants are exercised, it will raise $120 million in total and that's enough to take us comfortably into 2017. That is plenty of time turn sales around. With imminent BK off the table, the shorts may fall throw in the towel. Remember: markets don't bottom on good news.
Why would the deal fall-through between the CC and the PR an hour later?